Author

Paula Mandall

Observed names: Mandall, P, P. Mandall

Institution: The Christie NHS Foundation Trust

Observed institutions: St James's University Hospital, The Christie Hospital, The Christie NHS Foundation Trust

OpenAlex ID: A5016673126

Development of a patient-reported questionnaire for collecting toxicity data following prostate brachytherapy

2010 · Damian J.J. Farnell, Paula Mandall, et al. · Radiotherapy and Oncology · 30

Five‐year outcomes after iodine‐125 seed brachytherapy for low‐risk prostate cancer at three cancer centres in the UK

2013 · Peter D. Dickinson, Jahangeer Malik, et al. · British Journal of Urology · 18

Biochemical outcomes for patients with intermediate risk prostate cancer treated with I-125 interstitial brachytherapy monotherapy

2013 · Anna Thi Huyen Tran, Paula Mandall, et al. · Radiotherapy and Oncology · 14

Patient-reported Outcomes and Health-related Quality of Life in Prostate Cancer Treated with a Single Fraction of High Dose Rate Brachytherapy Combined with Hypofractionated External Beam Radiotherapy

2014 · A. Choudhury, C. Arthur, et al. · Clinical Oncology · 12

Report on the Early Efficacy and Tolerability of I125 Permanent Prostate Brachytherapy from a UK Multi-institutional Database

2008 · D.M. Mitchell, P. Mandall, et al. · Clinical Oncology · 10

Single-fraction high-dose-rate (HDR) brachytherapy boost and hypofractionated radiation for intermediate- and high-risk prostate cancer: A report of toxicity from a single center experience.

2012 · Claire Arthur, Nooreen Sarah Alam, et al. · Journal of Clinical Oncology · 1

Po-230 Single Fraction Hdr Brachytherapy and Ebrt for Prostate Cancer: an Analysis of Health Related Quality of Life

2012 · J. Malik, C. Arthur, et al. · Radiotherapy and Oncology

Biochemical outcomes for patients with intermediate-risk, organ-confined prostate cancer treated with I-125 interstitial brachytherapy monotherapy.

2012 · Anna Thi Huyen Tran, Paula Mandall, et al. · Journal of Clinical Oncology

Multi-institutional outcomes following LDR brachytherapy in patients with higher-risk prostate cancer.

2012 · Ruth Conroy, Peter Hoskin, et al. · Journal of Clinical Oncology

Multi-institutional Outcome Following LDR Brachytherapy in Patients with Higher Risk Prostate Cancer

2012 · R. Conroy, P. Hoskin, et al. · Clinical Oncology

Single Fraction HDR Boost and Dose Escalation for Intermediate and High Risk Prostate Cancer. A Report of Toxicity from a Single Centre Experience

2012 · C. Arthur, P. Mandall, et al. · Clinical Oncology

Acute Toxicity after Single Fraction High Dose Rate Brachytherapy with External Beam Radiotherapy in Intermediate and High Risk Prostate Cancer

2009 · N. Alam, C. Taylor, et al. · Clinical Oncology

9431 The role of radiotherapy for aggressive fibromatosis

2009 · N. Alam, S. Tolan, et al. · European Journal of Cancer Supplements

Multi-institutional UK Prostate Brachytherapy Database

2007 · J.P. Wylie, P. Mandall, et al. · Clinical Oncology

Multi-institutional UK prostate brachytherapy database

2007 · Wylie, JP, Mandall, P, et al. · UCL Discovery (University College London)

Works count: 15

Citation count: 85

H-index: 5

I10-index: 5